These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28669850)

  • 1. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
    Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
    World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.
    Li H; Wang H; Peng C; Zheng X; Liu J; Weng ZH; Yang DL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):547-555. PubMed ID: 28786051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT; Zhang YF; Sun BH; Dai Y; Zhu HL; Xu YH; Lu MJ; Yang DL; Li X; Zhang ZH
    World J Gastroenterol; 2015 May; 21(18):5668-76. PubMed ID: 25987794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.
    Huang R; Yang CC; Liu Y; Xia J; Su R; Xiong YL; Wang GY; Sun ZH; Yan XM; Lu S; Wu C
    World J Gastroenterol; 2015 Sep; 21(34):9957-65. PubMed ID: 26379400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
    Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
    Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
    Fan R; Sun J; Yuan Q; Xie Q; Bai X; Ning Q; Cheng J; Yu Y; Niu J; Shi G; Wang H; Tan D; Wan M; Chen S; Xu M; Chen X; Tang H; Sheng J; Lu F; Jia J; Zhuang H; Xia N; Hou J;
    Gut; 2016 Feb; 65(2):313-20. PubMed ID: 25586058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting.
    Yu W; Wang Y; Shen C; Ji R; Zhang L; Zhao X; Su M; Zhang Y; He W; Cao J; Hao Y; Chen S; Zhao C
    Braz J Infect Dis; 2017; 21(3):213-218. PubMed ID: 28351603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.